RxDoctor Payments Data

Darren Mack, MD

Urology · Aiken, SCNPI 1366679318

Payments from drug & device makers

$5,493in general payments, 2019–2025

Across 235 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Coloplast$494
  • Boston Scientific$248
  • AbbVie$161
  • Sumitomo Pharma America, Inc.$160
  • Astellas Pharma US Inc$146
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$1,23122%
  • Food & beverage$4,23377%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,493 in reported general payments places this provider in the 60th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$271,059
Medicare patients
832
Services billed
2,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron49$60,128
GemtesaVibegron20$15,149
Tamsulosin Hcl414$6,545
Finasteride179$3,235
Estradiol22$2,258
Solifenacin Succinate51$1,447
Tadalafil13$1,315
Testosterone Cypionate33$880
Potassium Citrate ErPotassium Citrate13$830
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$714
Oxybutynin Chloride37$655
Bicalutamide13$606
Alfuzosin Hcl ErAlfuzosin Hcl19$571
Ketorolac Tromethamine26$502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$146$60,12849 claims
Sumitomo Pharma America, Inc.Gemtesa$160$15,14920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 196 urology providers in South Carolina.

Other urology in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →